JUMPCAN(SH:600566) Zheng Quan Zhi Xing·2025-08-06 09:09Core Viewpoint - The legal opinion letter from Grandall Law Firm (Shanghai) confirms that Hubei Jichuan Pharmaceutical Co., Ltd. has obtained the necessary approvals and authorizations for the cancellation of certain stock options and the repurchase of restricted stocks, in accordance with relevant laws and regulations [2][12]. Group 1: Approval and Authorization - The company held multiple board meetings and a shareholders' meeting in 2022 and 2023 to approve the incentive plan and related matters, with independent directors providing their consent [5][6][7]. - The legal opinion states that the company has complied with the necessary legal requirements and has conducted thorough verification of the facts and legal issues related to the incentive plan [3][4]. Group 2: Details of Cancellation and Repurchase - The company plans to cancel a total of 264,000 stock options and repurchase 219,000 restricted stocks due to the departure of 9 incentive recipients, and an additional 318,500 stock options and restricted stocks due to the demotion of 22 recipients [9][10]. - The repurchase price for the restricted stocks will be based on the grant price plus interest from the People's Bank of China, with specific prices set for different batches of stocks [10]. Group 3: Funding and Disclosure - The funding for the repurchase will come from the company's own funds, and a dedicated securities account has been established for this purpose [10]. - The company has fulfilled its obligation to disclose information regarding the repurchase and cancellation, with announcements made in accordance with regulatory requirements [11][12].